A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
The DOI matches its Crossref record.
Abstract
We examined the effects of 3 dosages of pridopidine, a dopamine‐stabilizing compound, on motor function and other features of Huntington's disease, with additional evaluation of its safety and tolerability. This was a randomized, double‐blind, placebo‐controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty‐seven subjects enrolled from October 24, 2009, to May 10, 2010. The intervention was pridopidine, either 20 (n=56), 45 (n=55), or 90 (n=58) mg daily for 12 weeks or matching placebo (n=58). The primary outcome measure was the change from baseline to week 12 in the Modified Motor Score, a subset of the Unified Huntington's Disease Rating Scale Total Motor Score. Measures of safety and tolerability included adverse events and trial completion on the assigned dosage. After 12 weeks, the treatment effect (relative to placebo, where negative values indicate improvement) of pridopidine 90 mg/day on the Modified Motor Score was −1.2 points (95% confidence interval [CI], −2.5 to 0.1 points; P = .08). The effect on the Total Motor Score was −2.8 points (95% CI, −5.4 to −0.1 points; nominal P = .04). No significant effects were seen in secondary outcome measures with any of the active dosages. Pridopidine was generally well tolerated. Although the primary analysis did not demonstrate a statistically significant treatment effect, the overall results suggest that pridopidine may improve motor function in Huntington's disease. The 90 mg/day dosage appears worthy of further study. Pridopidine was well tolerated. © 2013 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Clinical Features of Huntington’s Disease
Ghosh, R., & Tabrizi, S. J. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-71779-1_1 · Cited by 202
Therapeutic Advances for Huntington’s Disease
Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 164
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Sigma-1 receptor: a potential therapeutic target for traumatic brain injury
Shi, M., Chen, F., Chen, Z., Yang, W., Yue, S., Zhang, J., & Chen, X. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.685201 · Cited by 58
“Recent clinical trials have reported that Sig1R agonist Pridopidine has neuroprotective efficacy in treating motor deficits of HD patients (Lundin et al., 2010; Huntington Study Group, 2013; Reilmann et al., 2019).”
BackgroundFarr, O. M., Zhang, S., Hu, S., Matuskey, D., Abdelghany, O., Malison, R. T., & Li, C.-S. R. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000674 · Cited by 57
Metadata
- Authors
- The Huntington Study Group HART Investigators
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2013-02-28
- Volume
- 28
- Issue
- 10
- Pages
- 1407-1415
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2740215628
- Cited by
- 127
- References
- 0
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.